Related Experiment Video
Updated: May 21, 2026
14:48
Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury
Published on: March 21, 2021
CXCR2 in acute lung injury
1Department of Anesthesiology and Intensive Care Medicine, University Hospital of Tübingen, 72076 Tübingen, Germany.
Mediators of Inflammation
|June 22, 2012
Summary
Blocking CXC chemokine receptor 2 (CXCR2) may treat acute lung injury. A new oral CXCR1 and CXCR2 antagonist shows promise in human trials for pulmonary inflammation.
Area of Science:
- Immunology
- Pharmacology
- Pulmonary Medicine
Background:
- Neutrophil recruitment is crucial for host defense during pulmonary inflammation.
- Uncontrolled neutrophil transmigration into the lung characterizes acute lung injury and acute respiratory distress syndrome.
- Chemokines, particularly those acting on CXC chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2 (CXCR2), drive leukocyte extravasation.
Purpose of the Study:
- To review the role of CXCR2 in acute lung injury (ALI).
- To discuss the therapeutic potential of targeting CXCR2 in ALI.
- To highlight a novel orally administered CXCR1 and CXCR2 antagonist evaluated in humans.
Main Methods:
- Review of existing literature on CXCR2 function in inflammation.
- Analysis of studies involving CXCR1/2 antagonists in experimental models.
- Discussion of recent human trial data for a new CXCR1 and CXCR2 antagonist.
Main Results:
- CXCR2 plays a pivotal role in the development and progression of inflammatory disorders, including ALI.
- ELR(+) chemokines activate CXCR2, promoting neutrophil migration.
- A new orally administered CXCR1 and CXCR2 antagonist has demonstrated efficacy in humans.
Conclusions:
- CXCR2 is a significant therapeutic target for acute lung injury.
- Dual CXCR1/2 antagonism offers a promising strategy for managing pulmonary inflammation.
- Novel orally available antagonists represent a potential advancement in treating ALI.
Related Concept Videos
01:21Acute Respiratory Failure-II
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
01:29Acute Respiratory Failure-V
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:08Pneumothorax II: Pathophysiology
Pneumothorax means the presence of air in the pleural space — the thin potential gap between the visceral and parietal pleura. This condition disrupts the normal pressure balance that keeps the lungs inflated, leading to partial or complete collapse of the affected lung.Normal physiologyUnder normal conditions, the pleural space maintains a slightly negative intrapleural pressure, which keeps the lungs expanded against the chest wall. This negative pressure creates a delicate balance between...